{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:39:41Z","timestamp":1787567981786,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Mol Morphol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) have become an important therapeutic option for oral cancers; however, reliable biomarkers predicting treatment efficacy remain limited. In this study, we investigated the association between intratumoral immune cell subsets, regional lymph node (RLN) immune status, and clinical responses to ICIs in patients with recurrent oral cancer. Pretreatment tumor tissues and RLNs were analyzed by immunohistochemistry to evaluate tumor-infiltrating lymphocytes, including CD8\n                    <jats:sup>+<\/jats:sup>\n                    , CD103\n                    <jats:sup>+<\/jats:sup>\n                    , CD3\n                    <jats:sup>+<\/jats:sup>\n                    , ICOS\n                    <jats:sup>+<\/jats:sup>\n                    , and CD163\n                    <jats:sup>+<\/jats:sup>\n                    cells, as well as programmed death-ligand 1 (PD-L1) expression and CD169\n                    <jats:sup>+<\/jats:sup>\n                    sinus macrophages. Treatment responses were assessed according to RECIST version 1.1. Responders to ICIs exhibited higher densities of CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD103\n                    <jats:sup>+<\/jats:sup>\n                    T cells compared with non-responders, whereas no significant associations were observed for CD3\n                    <jats:sup>+<\/jats:sup>\n                    , ICOS\n                    <jats:sup>+<\/jats:sup>\n                    , CD163\n                    <jats:sup>+<\/jats:sup>\n                    cells, or PD-L1 expression. Elevated pretreatment serum C-reactive protein (CRP) levels were associated with poorer responses. CD169\n                    <jats:sup>+<\/jats:sup>\n                    sinus macrophages in RLNs did not correlate significantly with treatment efficacy or T-cell infiltration. These findings suggest that intratumoral effector and tissue-resident memory\u2013like T-cell infiltration, together with systemic inflammatory status, may influence ICI efficacy in recurrent oral cancer, and could improve patient stratification for immunotherapy.\n                  <\/jats:p>","DOI":"10.1007\/s00795-026-00473-3","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:03:48Z","timestamp":1787565828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased density of CD103-positive tissue-resident memory T cells predicts favorable response to immunotherapy in oral cancers"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6831-6573","authenticated-orcid":false,"given":"Mayuko","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Komohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Hirosue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-0268","authenticated-orcid":false,"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"473_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ijom.2025.01.010","volume":"54","author":"T Ooyama","year":"2025","unstructured":"Ooyama T, Hirayama M, Seki Y, Iwamoto A, Yoshida R, Nakayama H (2025) Pretreatment nutritional indices are associated with survival and T-cell exhaustion in recurrent or metastatic oral squamous cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective cohort study. Int J Oral Maxillofac Surg 54:685\u2013694","journal-title":"Int J Oral Maxillofac Surg"},{"key":"473_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310","journal-title":"Immunity"},{"key":"473_CR3","first-page":"101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, Yu Z, He J, Liang W (2021) The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. E Clin Med 41:101134","journal-title":"E Clin Med"},{"key":"473_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","volume":"6","author":"F Mami-Chouaib","year":"2018","unstructured":"Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihy I, Tartour E (2018) Resident memory T cells, critical components in tumor immunology. J Immunother Cancer 6:87","journal-title":"J Immunother Cancer"},{"key":"473_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1186\/s12885-023-11438-5","volume":"23","author":"S Natsuki","year":"2023","unstructured":"Natsuki S, Tanaka H, Nishiyama M, Deguchi S, Miki Y, Yoshii M, Tamura T, Toyokawa T, Lee S, Maeda K (2023) Significance of CD103+ tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer. BMC Cancer 23:1011","journal-title":"BMC Cancer"},{"key":"473_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/1348-0421.13220","volume":"69","author":"M Yamashita","year":"2025","unstructured":"Yamashita M, Yano H, Komohara Y, Yamada R, Fujiwara Y, Hirayama M, Seki Y, Yoshida R, Nakayama H (2025) Cytotoxic T lymphocyte density and PD-L1 expression predict the response to anti-PD1 therapy in recurrent oral squamous cell carcinoma. Microbiol Immunol 69:350\u2013358","journal-title":"Microbiol Immunol"},{"key":"473_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/cas.12212","volume":"104","author":"K Ohnishi","year":"2013","unstructured":"Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, Takeya M (2013) CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci 104:1237\u20131244","journal-title":"Cancer Sci"},{"key":"473_CR8","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00262-022-03149-w","volume":"71","author":"S Kawaguchi","year":"2022","unstructured":"Kawaguchi S, Kawahara K, Fujiwara Y, Ohnishi K, Pan C, Yano H, Hirosue A, Nagata M, Hirayama M, Sakata J, Nakashima H, Arita H, Yamana K, Gohara S, Nagao Y, Maeshiro M, Iwamoto A, Hirayama M, Yoshida R, Komohara Y, Nakayama H (2022) Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration. Cancer Immunol Immunother 71:2127\u20132139","journal-title":"Cancer Immunol Immunother"},{"key":"473_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.immuni.2010.12.011","volume":"34","author":"K Asano","year":"2011","unstructured":"Asano K, Nabeyama A, Miyake Y, Qiu C-H, Kurita A, Tomura M, Kanagawa O, Fujii S-i, Tanaka M (2011) CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34:85\u201395","journal-title":"Immunity"},{"key":"473_CR10","doi-asserted-by":"publisher","first-page":"108993","DOI":"10.1016\/j.celrep.2021.108993","volume":"35","author":"C Tacconi","year":"2021","unstructured":"Tacconi C, Commerford CD, Dieterich LC, Schwager S, He Y, Ikenberg K, Friebel E, Becher B, Tugues S, Detmar M (2021) CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasis. Cell Rep 35:108993","journal-title":"Cell Rep"},{"key":"473_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00795-025-00433-3","volume":"58","author":"Y Ibe","year":"2025","unstructured":"Ibe Y, Ozaki Y, Anami T, Yano H, Fujiwara Y, Nishizawa H, Kurahashi R, Motoshima T, Murakami Y, Yatsuda J, Komohara Y, Kamba T (2025) Aging potentially reduces CD169 expression in sinus macrophages of pelvic lymph nodes. Med Mol Morphol 58:290\u2013297","journal-title":"Med Mol Morphol"},{"key":"473_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3960\/jslrt.17017","volume":"57","author":"T Nakagawa","year":"2017","unstructured":"Nakagawa T, Ohnishi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y (2017) Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin-fixed paraffin-embedded tissue samples. J Clin Exp Hematop 57:31\u201336","journal-title":"J Clin Exp Hematop"},{"key":"473_CR13","doi-asserted-by":"publisher","first-page":"36956","DOI":"10.1038\/srep36956","volume":"6","author":"HR Kim","year":"2016","unstructured":"Kim HR, Ha S-J, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO (2016) PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 6:36956","journal-title":"Sci Rep"},{"key":"473_CR14","doi-asserted-by":"publisher","first-page":"e70013","DOI":"10.1002\/cti2.70013","volume":"13","author":"C Pan","year":"2024","unstructured":"Pan C, Fujiwara Y, Yano H, Anami T, Ibe Y, Li L, Miura Y, Motoshima T, Esumi S, Yatsuda J, Hibi T, Kamba T, Komohara Y (2024) The contribution of the CRP\/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages. Clin Transl Immunol 13:e70013","journal-title":"Clin Transl Immunol"},{"key":"473_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells14100741","volume":"14","author":"AF Saeed","year":"2025","unstructured":"Saeed AF (2025) Tumor-associated macrophages: polarization, immunoregulation, and immunotherapy. Cells 14:741","journal-title":"Cells"},{"key":"473_CR16","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1158\/0008-5472.CAN-17-2011","volume":"78","author":"D Shiraishi","year":"2018","unstructured":"Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J, Cheng P, Nakagata N, Mizuta H, Bekki H, Nakashima Y, Oda Y, Takeya M, Komohara Y (2018) CD163 is required for protumoral activation of macrophages in human and murine sarcoma. Cancer Res 78:3255\u20133266","journal-title":"Cancer Res"},{"key":"473_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ijo.2016.3785","volume":"50","author":"M Hirai","year":"2017","unstructured":"Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S (2017) Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol 50:41\u201348","journal-title":"Int J Oncol"},{"key":"473_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cre2.590","volume":"8","author":"R Nocini","year":"2022","unstructured":"Nocini R, Vianini M, Girolami I, Calabrese L, Scarpa A, Martini M, Morbini P, Marletta S, Brunelli M, Molteni G, Parwani A, Pantanowitz L, Eccher A (2022) PD-L1 in oral squamous cell carcinoma: a key biomarker from the laboratory to the bedside. Clin Exp Dent Res 8:690\u2013698","journal-title":"Clin Exp Dent Res"},{"key":"473_CR19","doi-asserted-by":"publisher","first-page":"104722","DOI":"10.1016\/j.oraloncology.2020.104722","volume":"106","author":"D Lenouvel","year":"2020","unstructured":"Lenouvel D, Gonz\u00e1lez-Moles M\u00c1, Ruiz-\u00c1vila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-Garc\u00eda P (2020) Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis. Oral Oncol 106:104722","journal-title":"Oral Oncol"},{"key":"473_CR20","doi-asserted-by":"publisher","first-page":"35056","DOI":"10.1038\/srep35056","volume":"6","author":"J-F Tu","year":"2016","unstructured":"Tu J-F, Ding Y-H, Ying X-H, Wu F-Z, Zhou X-M, Zhang D-K, Zou H, Ji J-S (2016) Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep 6:35056","journal-title":"Sci Rep"},{"key":"473_CR21","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/jimmun\/vkaf040","volume":"214","author":"Y Luo","year":"2025","unstructured":"Luo Y, Li H, Fang H, Gong T, Zhao Y, Cao W, Yu M, Wang T, Lin H, Zhong M (2025) ICOS+ CD4+ T cells promote antitumor immunity through Akt\/STAT1\/T-bet axis in MSS\/pMMR colorectal cancer. J Immunol 214:1422\u20131433","journal-title":"J Immunol"}],"container-title":["Medical Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00473-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00795-026-00473-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00473-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:03:50Z","timestamp":1787565830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00795-026-00473-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":21,"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s00795-026-00473-3","relation":{},"ISSN":["1860-1480","1860-1499"],"issn-type":[{"value":"1860-1480","type":"print"},{"value":"1860-1499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no financial competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the Institutional Review Board of Kumamoto University (#2059) in accordance with the guidelines for Good Clinical Practice and the tenets of the Declaration of Helsinki. The need for individual patient consent for inclusion in the study was waived by the Institutional Review Board of Kumamoto University (#2059) since the present study was a retrospective analysis. However, the patients were given the opportunity to refuse participation by opting out of the study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}